Ab­b­Vie beefs up the on­col­o­gy pipeline, bag­ging an up­start STING play­er with its own unique ap­proach

Ab­b­Vie isn’t let­ting its $63 bil­lion buy­out of Al­ler­gan stop its M&A/deals team from con­tin­u­ing their work.

Mon­day morn­ing we learned that the phar­ma gi­ant is snap­ping up tiny Mavuphar­ma out of Seat­tle, a Fra­zier-backed start­up that has its own unique take on STING — which is on the thresh­old of their first clin­i­cal tri­al.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER